Esketamine (Intranasal Spray)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, The University of Texas Health Science Center at San Antonio, Riccardo Guglielmo

Conditions

AnhedoniaAnxietyApathyCognitionDepression and Quality of LifePost Traumatic Stress Disorder PTSDPsychiatric ComorbiditiesTemperament

Phase 1

Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

CompletedNCT06795659

The University of Texas Health Science Center at San AntonioPost Traumatic Stress Disorder PTSD

Start: 2025-06-09End: 2026-01-16Updated: 2026-01-28

Phase 3

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

CompletedNCT02497287

Janssen Research & Development, LLCTreatment-resistant Depression

Start: 2015-09-30End: 2017-10-28Updated: 2025-04-29

Unknown Phase

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

RecruitingNCT07146503

Riccardo GuglielmoAnhedonia, Anxiety, Apathy +5

Start: 2022-11-01End: 2030-08-01Target: 100Updated: 2026-03-31

Related Papers

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study

Frontiers in Psychiatry2024-10-073 citations

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry2023-10-316 citations

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

Frontiers in Psychiatry2023-10-314 citations

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

The International Journal of Neuropsychopharmacology2022-12-1411 citations

Longitudinal Course of Adverse Events With Esketamine Nasal Spray

The Journal of Clinical Psychiatry2022-09-1614 citations

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression

The Journal of Clinical Psychiatry2020-04-20261 citations

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

The International Journal of Neuropsychopharmacology2020-04-0717 citations

142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression

CNS Spectrums2020-04-013 citations